EP-1611: HDR intestinal brachytherapy as a salvage treatment in rectal adenocarcinoma patients

D.K. Kazberuk, T.F. Filipowski, W.M. Markiewicz, D.H. Hempel, M.N. Niksa, A.S.Z.T. Szmigiel-Trzcinska, J.T.B. Topczewska-Bruns, B.P.J. Pancewicz-Janczuk
2015 Radiotherapy and Oncology  
Simulation phase: given the statistical nature of these relationships, we reserved one cartridge of each connectors type to assure that we would not run out of them when the surgical procedure took place. A retrospectively application of these formulae yielded that we would had used only those corresponding A, B, C reserved cartridges in 14%, 19% and 12% of the procedures. We would have had only to add that spent cartridge when placing the following order. Conclusions: When LDR-brachytherapy
more » ... DR-brachytherapy seeds implant with needle loading on demand technique is used the quantity of the different types of seed connectors can be statistically expressed in terms of the preoperative prostate volume. With enough experience in the implant technique and preoperative prostate volumetric study it is possible to mark out institution-specific bounds to each of these quantities. It optimizes the preoperative prediction of seeds connectors, seeds and needles that will be used and reduces costs in material and storage. Purpose/Objective: To analyze the twelve years outcomes of I-125 LDR brachytherapy in Turkish men with lowintermediate risk localized prostate cancer. Materials and Methods: Between 2000Between -2004 patients treated with LDR brachytherapy were analyzed retrospectively. Brachytherapy was monotherapy in 127 pts.and used with external beam radiotherapy in 12 pts. Four pts excluded from study due to protocol deviation. 135 pts were analyzed for disease control and survival. For all the pts preplanning was done in treatment conditions. During the aplication real time planning was used. Four-six weeks after application postplanning dosimetry was done with CT and MR images. In dosimetry D90, V100, V150, V200, V250 for prostate; V100, V150 for urethra ; V100, dose at 4 cc for rectum were evaluated. Survival curves were calculated using the Kaplan-Meier method, and the significance was calculated by the log-rank test. To compare the prognostic factors Chi-square test was used. Results: The median follow-up time was 88 months ( 6-170 months). The median age of 135 pts. Was 65 years (44-81 years). In pts 64.4 % of them were in low risk and 35.6 % in intermediate risk. The mean PSA value at diagnosis was 8,12 ng/ml (SD ±6,33). In 43.2 % of the pts received androgen deprivation for 3 months before procedure . T stages were T1c in 12 pts, T2a in 64 pts, T2b in 53 pts and T3 in 6 pts. During procedure median 28 (18-35) needles and 85 (65-110) seeds at 0.49 U/seed(0.43-0.50) were used. Prescribed dose was set at 145 Gy in monotherapy and 110 Gy in combined treatment. Treatment results were given in table 1. Conclusions: Our results are in concordance and comparable with other reports on I-125 LDR prostate brachytherapy. Electronic Poster: Brachytherapy track: Anorectal EP-1611 HDR intestinal brachytherapy as a salvage treatment in rectal adenocarcinoma patients
doi:10.1016/s0167-8140(15)41603-2 fatcat:4vwrjbmr5bdazamwoq2c2te4la